Will PI3K-targeted therapies for cancer become a reality?

In a recent issue of Annals of Oncology, Vuylsteke and colleagues presented the interim analysis of phase II PEGGY study on the use of pictilisib [a pan-phosphoinositide-3-kinase (PI3K) inhibitor] plus paclitaxel in hormone receptor positive human epidermal receptor 2 (HER2) negative (ER+/HER2−) locally advanced or metastatic breast cancer (1). This clinical trial is one among the many clinical clinicals to report clinical benefits and toxicity associated with PI3K-targeted therapies.